Pharm Exec2h
ADRIATIC Trial Demonstrates Significant Survival Benefit in LS-SCLC, Potentially Shaping Future Treatment Standards
Nancy Ghattas, VP, US franchise head, imunno-oncology, gastrointestinal tumors, AstraZeneca, discusses the promising results ...
Pharm Exec2h
Roche Appoints Wafaa Mamilli as Chief Digital Technology Officer
Effective February 10, 2025, Mamilli will assume global responsibility for the Informatics function for the Roche Group.
Pharm Exec2h
Essen Health Care Selected to Test Medicare Dementia Care Model
Essen Health Care announced that it is participating in the Guiding an Improved Dementia Experience (GUIDE) Model, an ...
Pharm Exec3h
FDA Approves Novo Nordisk’s Ozempic to Reduce Kidney Disease in Patients with Type 2 Diabetes, Chronic Kidney Disease
Approval was based on results from the Phase IIIb FLOW trial, which demonstrated a 24% relative risk reduction in kidney ...
Pharm Exec8h
Treating Disruptive Symptom’s in Crohn’s Patients: Q&A with Mark Genovese, MD
Mark Genovese: Crohn’s disease is a chronic, inflammatory bowel disease associated with progressive bowel damage, disability, ...
Pharm Exec22h
New Spravato Indication Offers Greater Flexibility and Personalization for Patients with Treatment-Resistant Depression
Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the ...